Finally, in the context of progressive MS, inhibitors of the angiotensin converting enzyme were proposed to be of therapeutic utility as off the shelf commercially-available TGFB1 inhibitors [12,13,14,16]. This evidence concerns the gene TGFB1 and myeloid sarcoma.